The North America Human leukocyte antigens (HLAs) typing transplant diagnostics services market is witnessing significant growth due to the increasing demand for precise and personalized transplantation procedures. With advanced diagnostic services, healthcare providers in North America are able to accurately match donors with recipients, improving transplant success rates and patient outcomes. The region's well-established healthcare infrastructure, technological advancements, and high investment in research and development contribute to the growth of the market, ensuring efficient and effective transplant diagnostics for better patient care.
Access Full Report: https://databridgemarketresearch.com/reports/north-america-hla-typing-transplant-diagnostics-services-market
Data Bridge Market Research analyses that the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market is expected to grow at a CAGR of 8.7% in the forecast period of 2022 to 2029. In North America, the increasing incidence of organ failure and the scarcity of suitable organs for transplantation have created a significant demand for HLAs typing transplant diagnostics services. Accurate HLA typing is essential for ensuring compatibility between donors and recipients, enhancing transplant success rates, and addressing the urgent need for life-saving organ transplants.
Key Findings of the Study
The growing importance of precision medicine is expected to drive the market's growth rate
The growing importance of precision medicine in North America has highlighted the need for accurate HLA typing in transplant diagnostics services. Precision medicine aims to customize treatments based on individual genetic makeup, and HLA typing plays a crucial role in identifying the most compatible donors for transplant procedures. To ensure a better match between donors and recipients, precise HLA typing helps to minimize the risk of organ rejection and improve patient outcomes in the field of transplantation.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2022 to 2029
|
Base Year
|
2021
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Product and Services (Instruments, Reagents and Consumables, Software, Services), Application (Diagnostics, Research), End-user (Hospitals, Academic and Research Institutes), Organ Type (Kidney, Liver, Heart, Lung, Pancreas, Others), Technology (Polymerase Chain Reaction, Next-Generation Sequencing)
|
Countries Covered
|
U.S., Canada and Mexico in North America
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Siemens (Germany), BD (U.S.), Thermo Fisher Scientific (U.S.), QIAGEN (Germany), ProImmune Ltd. (U.K.), Creative Biolabs (U.S.), HistoGenetics LLC (U.S.), UCLA Health (U.S.), Quick Biology Inc. (U.S.), TBG Diagnostics Limited (Australia), Fujirebio (Japan), Medtronic (Ireland), Omixon Inc. (Hungary), Takara Bio Inc. (Japan), Biofortuna Limited (U.K.), Luminex Corporation (U.S.), Hologic, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Bio-Rad Laboratories, Inc. (U.S.) among others
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The human leukocyte antigens (HLAs) typing transplant diagnostics services market is segmented on the basis of product and services, application, end-user, organ type, and technology
- On the basis of product and services, the human leukocyte antigens (HLAs) typing transplant diagnostics services market is segmented into instruments, reagents and consumables, software and services.
- On the basis of application, the human leukocyte antigens (HLAs) typing transplant diagnostics services market is segmented into diagnostics and research.
- On the basis of end-user, the human leukocyte antigens (HLAs) typing transplant diagnostics services market is segmented into hospitals, and academic and research institutes.
- On the basis of organ type, the human leukocyte antigens (HLAs) typing transplant diagnostics services market is segmented into kidney, liver, heart, lung, pancreas, and others.
- On the basis of technology the market is segmented into polymerase chain reaction and next-generation sequencing. The polymerase chain reaction is further segmented into PCR-SSP, PCR SSOP, and PCR-SBT.
Major Players
Data Bridge Market Research recognizes the following companies as the major human leukocyte antigens (HLAS) typing transplant diagnostics services market players in human leukocyte antigens (HLAS) typing transplant diagnostics services market are Creative Biolabs (U.S.), HistoGenetics LLC (U.S.), UCLA Health (U.S.), Quick Biology Inc. (U.S.), TBG Diagnostics Limited (Australia), Fujirebio (Japan), Medtronic (Ireland), Omixon Inc. (Hungary), Takara Bio Inc. (Japan), Biofortuna Limited (U.K.),
Market Developments
- In 2022, Mylab Discovery Solutions launched DiscoverSeries HLAB*27 detection kit, an in-vitro diagnostic test for Ankylosing Spondylitis (AS).
- In 2022, Genome Diagnostics (GenDx), a Dutch molecular diagnostics firm received approval from Canadian regulators for the invitro diagnostic use of its NGSgo-MX11-3 human leukocyte antigen genotyping test.
Regional Analysis
Geographically, the countries covered in the human leukocyte antigens (HLAs) TYPING transplant diagnostics services market report are U.S., Canada, and Mexico in North America
As per Data Bridge Market Research analysis:
The U.S. dominates the North America region in the human leukocyte antigens (HLAs) typing transplant diagnostics services market during the forecast period 2022-2029
The U.S. dominates the North America market for HLAs typing transplant diagnostics services due to the high prevalence of chronic diseases such as cancer, cardiac diseases, and renal-associated diseases in the country. The rising incidence of these diseases has led to an increased demand for transplant procedures, driving the need for accurate HLA typing to ensure successful and compatible organ transplantation. The advanced healthcare infrastructure and research advancements in the U.S. further contribute to its dominance in the market.
Canada is emerging as a dominant player in the human leukocyte antigens (HLAs) typing transplant diagnostics services market for the forecast period 2022-2029
Canada is emerging as a dominant player in the North American market for HLAs typing transplant diagnostics services due to the increasing prevalence of chronic diseases like cancer, cardiac diseases, and renal-associated diseases in the country. The growing demand for transplant procedures to address these conditions has driven the need for accurate HLA typing to ensure successful organ transplantation. Canada's robust healthcare infrastructure, advanced medical research, and focus on patient care contribute to its dominance in the market.
For more detailed information about the human leukocyte antigens (HLAs) typing transplant diagnostics services market report, click here – https://www.databridgemarketresearch.com/jp/reports/north-america-hla-typing-transplant-diagnostics-services-market